Session » Systemic Sclerosis & Related Disorders – Clinical Poster II
- 9:00AM-11:00AM
-
Abstract Number: 1652
Anticentromere Antibody Levels and Isotypes Associate with Disease Severity in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1631
Assessment of the Repeatability and Convergent Validity with Dermal Collagen of High Frequency Ultrasound in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1642
Automated Nailfold Capillary Counting System (AUTOCAPI) in Systemic Sclerosis Patients with Different Capillaroscopic Patterns
- 9:00AM-11:00AM
-
Abstract Number: 1650
Baseline Skin Score, Older Age and CD34-selection Influence the Outcome of Autologous Stem Cell Transplantation for Systemic Sclerosis – Results of a Prospective Non-interventional Study from the European Society for Blood & Marrow Transplantation (EBMT)
- 9:00AM-11:00AM
-
Abstract Number: 1641
Change in Calcinosis over 1 Year Using the SCTC Radiologic Scoring System for Calcinosis of the Hands in Patients with Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1645
Comparison of Automated Capture and Analysis System of Sublingual Microvessels and Nailfold Videocapillarscopy for Microvascular Assessment in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1634
Comparison of Different Pulmonary Hypertension Screening Algorithms in Patients with Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1630
Contribution of Chest Wall Muscle Atrophy to Decline of Forced Vital Capacity in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
- 9:00AM-11:00AM
-
Abstract Number: 1635
Correlation Between Raynaud’s Condition Score, Nailfold Videocapillaroscopy and Laser Speckle Contrast Analysis in Secondary Raynaud’s Phenomenon Due to Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1640
Cutaneous and Musculoskeletal Clinical Characterization of a Cohort of Patients with Chronic Graft-versus-host Disease
- 9:00AM-11:00AM
-
Abstract Number: 1636
Effect of Anti-Topoisomerase I Antibody Status on Decline in Lung Function in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Data from the SENSCIS Trial
- 9:00AM-11:00AM
-
Abstract Number: 1644
Effects of Nintedanib in Patients with Diffuse and Limited Cutaneous Systemic Sclerosis and Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial
- 9:00AM-11:00AM
-
Abstract Number: 1643
Efficacy and Safety of Nintedanib in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analysis of the SENSCIS Trial by Corticosteroid Use
- 9:00AM-11:00AM
-
Abstract Number: 1653
Efficacy and Safety of Romilkimab in Diffuse Cutaneous Systemic Sclerosis (dcSSc): A Randomized, Double-Blind, Placebo-Controlled, 24-week, Proof of Concept Study
- 9:00AM-11:00AM
-
Abstract Number: 1639
Endoscopic Findings in a Scleroderma Cohort with and Without Interstitial Lung Disease
- 9:00AM-11:00AM
-
Abstract Number: 1654
Esophageal Dilation and Other Clinical Factors Associated with Pulmonary Function Decline in Patients with Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1632
Evidence-based Consensus Statements for the Identification and Management of Interstitial Lung Disease in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1656
Health-Related Quality of Life in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease (SSc-ILD): Impact of Lung Function on Patient-Reported Outcomes in a Randomized Phase III Trial
- 9:00AM-11:00AM
-
Abstract Number: 1655
Histologic Features Correlate with the Modified Rodnan Skin Score, Serum Inflammatory Markers, and Patient Reported Outcomes in Patients with Early, Diffuse Cutaneous Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1658
Impact of Visceral Involvement in the Characterization and Prognosis of Patients Without Skin Involvement Classified as Systemic Sclerosis (SSc) According to 2013 ACR/EULAR Criteria in a Large Single Cohort
- 9:00AM-11:00AM
-
Abstract Number: 1646
Incidence Rate and Prevalence of Valvular Heart Disease in Systemic Sclerosis: A Retrospective Cohort Study from a Single Institution
- 9:00AM-11:00AM
-
Abstract Number: 1659
Linaclotide for the Treatment of Gastrointestinal Symptoms in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1628
Lung Function Decline in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease in the SENSCIS Trial: Subgroup Analysis by Time Since First Non-Raynaud Symptom
- 9:00AM-11:00AM
-
Abstract Number: 1651
Multicenter Double-Blind, Proof-of-Concept, Randomized Placebo-Controlled Trial of Riociguat in Systemic Sclerosis-associated Digital Ulcers
- 9:00AM-11:00AM
-
Abstract Number: 1649
Mycophenolate Mofetil and Cyclophosphamide Improve Health-Related Quality of Life in Patients with Systemic Sclerosis Who Participated in SLS II
- 9:00AM-11:00AM
-
Abstract Number: 1633
Relationship Between YKL-40, VEGF, and IL-5 in Borderline mPAP and Pulmonary Hypertension in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1657
Sarcopenia in Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1660
Serial Sublingual Videomicroscopy in Systemic Sclerosis Clinic: Are the Microcirculation Measurements Correlated with Gastrointestinal Symptoms?
- 9:00AM-11:00AM
-
Abstract Number: 1638
Sexual Health in 60 Female Patients with Systemic Sclerosis
- 9:00AM-11:00AM
-
Abstract Number: 1629
Significance of Abnormal Nailfold Videocapillarscopy Among Patients with Raynaud’s Phenomenon And/or Suspected Connective Tissue Disease: A Cross-Sectional Single-Center US Experience
- 9:00AM-11:00AM
-
Abstract Number: 1648
Systemic Sclerosis Auto-antibody Profiles Predict Interstitial Lung Disease Onset but Not Progression
- 9:00AM-11:00AM
-
Abstract Number: 1637
The Clinical Features of Anti-RNA Polymerase III Antibodypositive Systemic Sclerosis with and Without Malignancy